Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106512 | 1.00 | PDGFRB (0.59) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL21769356 | 0.92 | PDGFRB (0.52) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL21769423 | 0.83 | FGFR2 (0.57) | PDGFRBPDGFRAFGFR2KDRSRC | |
| SCHEMBL371742 | 0.83 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL30106509 | 0.83 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL4462225 | 0.82 | PDGFRA (0.56) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29073410 | 0.82 | KDR (0.56) | PDGFRBPDGFRAFGFR2KDRSRC | |
| SCHEMBL23147176 | 0.81 | PDGFRB (0.54) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29811874 | 0.81 | PDGFRB (0.54) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL3795538 | 0.81 | PDGFRB (0.65) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842425-B1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-05-22 | — | — | EP | disclosed |
| CN-110857293-B | Novel quinoline derivative inhibitor | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-110857293-A | Novel quinoline derivative inhibitor | 南京药捷安康生物科技有限公司 | 2020-03-03 | — | — | CN | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | PDGFRB 136/4885PDGFRA 161/4885FGFR2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.